Journal of Stroke & Cerebrovascular Diseases
Volume 17, Issue 6 , Pages 356-359, November 2008

Titrated Initiation of Acetylsalicylic Acid-Dipyridamole Therapy Reduces Adverse Effects and Improves Tolerance in Patients With Stroke

  • André G. Douen, MD, PhD, FRCPC

      Affiliations

    • Department of Neurology, Trillium Health Centre, Mississauga, Ontario, Canada
    • Division of Neurology, University of Ottawa, Ontario, Canada
    • Corresponding Author InformationAddress correspondence to André G. Douen, MD, PhD, FRCPC, Director, Regional Stroke Prevention Clinic, Division of Neurology, Trillium Health Centre, 100 Queensway West, Mississauga, ON L5B 1B8 Canada.
  • ,
  • Sejla Medic, RN

      Affiliations

    • Department of Neurology, Trillium Health Centre, Mississauga, Ontario, Canada
  • ,
  • Mehreen Sabih, MBBS

      Affiliations

    • Department of Neurology, Trillium Health Centre, Mississauga, Ontario, Canada
  • ,
  • Nicole Pageau, RN, BA

      Affiliations

    • Department of Neurology, Trillium Health Centre, Mississauga, Ontario, Canada
  • ,
  • Ashfaq Shuaib, MD, FRCPC, FAHA

      Affiliations

    • Division of Neurology, University of Alberta, Edmonton, Canada

Received 14 December 2007; accepted 21 April 2008.

Background

Standard aspirin (acetylsalicylic acid [ASA])-dipyridamole therapy twice daily is associated with high rates of discontinuation in large part because of headache and gastrointestinal side effects. Attempts to address dipyridamole-induced headache through reduced dose initiation have produced variable results. Moreover, it has been suggested that migraineurs are more likely to have a dipyridamole-induced headache.

Objective

We sought to evaluate whether titrated initiation of ASA-dipyridamole in patients with stroke/transient ischemic attack (TIA) improves tolerance and to assess the appearance of headache in those with pre-existing history of headaches.

Methods

ASA-dipyridamole (25/200 mg) once daily together with ASA (81 mg) daily was started in 130 patients given the diagnosis of stroke/TIA with instructions to increase ASA-dipyridamole to twice daily after 7 days and discontinue ASA (81 mg). Patients received a telephone call on days 7 and 14 to assess for adverse events, discontinuation, and recurrent stroke/TIA.

Results

Two patients were lost to follow-up. After 2 weeks, 113 patients were using the medication without any major complications. Fifteen patients were off therapy; 10 (8%) patients stopped because of headache and/or gastrointestinal symptoms, whereas 4 patients were switched to other antiplatelet agents by their primary care physician as a matter of choice rather than ASA-dipyridamole side effects. One patient had recurrent stroke because of intracranial dissection and was switched to anticoagulation. Only 4 of 27 (14%) patients with a history of headache discontinued therapy.

Conclusions

Titrated initiation of ASA-dipyridamole (25/200 mg) appears to have low discontinuation rate and ∼90% tolerance after 2 weeks. History of migraine or tension headaches was not directly associated with discontinuation because of headaches.

Key Words: Stroke, transient ischemic attack, headache, aspirin, dipyridamole

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported through unrestricted educational grants from Boehringer Ingelheim, Canada (N. Pageau, S. Medic, M. Sabih).

PII: S1052-3057(08)00089-X

doi:10.1016/j.jstrokecerebrovasdis.2008.04.003

Journal of Stroke & Cerebrovascular Diseases
Volume 17, Issue 6 , Pages 356-359, November 2008